ImmunityBio, Inc.
IBRX
$7.87
-$0.20-2.42%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 164.89M | 140.64M | 112.98M | 81.92M | 56.09M |
| Total Other Revenue | 901.00K | 337.00K | 306.00K | 639.00K | 510.00K |
| Total Revenue | 165.79M | 140.98M | 113.29M | 82.56M | 56.60M |
| Cost of Revenue | 1.10M | 933.00K | 753.00K | 371.00K | 194.00K |
| Gross Profit | 164.70M | 140.04M | 112.54M | 82.18M | 56.41M |
| SG&A Expenses | 170.30M | 160.82M | 147.70M | 150.71M | 150.34M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 417.59M | 402.37M | 369.32M | 343.30M | 341.97M |
| Operating Income | -251.80M | -261.39M | -256.03M | -260.74M | -285.37M |
| Income Before Tax | -992.58M | -854.50M | -351.61M | -348.69M | -367.14M |
| Income Tax Expenses | -161.00K | 108.00K | -135.00K | 0.00 | 35.00K |
| Earnings from Continuing Operations | -992.42 | -854.60 | -351.47 | -348.69 | -367.17 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 62.00K | 69.00K | 74.00K | 77.00K | 79.00K |
| Net Income | -992.36M | -854.53M | -351.40M | -348.62M | -367.09M |
| EBIT | -251.80M | -261.39M | -256.03M | -260.74M | -285.37M |
| EBITDA | -235.30M | -245.41M | -240.60M | -244.95M | -269.07M |
| EPS Basic | -0.97 | -0.85 | -0.39 | -0.41 | -0.46 |
| Normalized Basic EPS | -0.60 | -0.53 | -0.24 | -0.25 | -0.29 |
| EPS Diluted | -0.97 | -0.85 | -0.39 | -0.42 | -0.49 |
| Normalized Diluted EPS | -0.60 | -0.53 | -0.24 | -0.25 | -0.29 |
| Average Basic Shares Outstanding | 4.01B | 3.85B | 3.68B | 3.42B | 3.17B |
| Average Diluted Shares Outstanding | 4.01B | 3.85B | 3.68B | 3.42B | 3.17B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |